董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barbara Troupin | 女 | Director | 58 | 6.40万美元 | 8.00 | 2026-05-28 |
| Charles McDermott | 男 | Director | 54 | 6.15万美元 | 16.05 | 2026-05-28 |
| Daniel M. Bradbury | 男 | Chairman of the Board and Director | 64 | 17.73万美元 | 397.86 | 2026-05-28 |
| Mark Pruzanski | 男 | Director | 58 | 6.33万美元 | 14.06 | 2026-05-28 |
| Martha J. Demski | 女 | Director | 73 | 7.65万美元 | 14.06 | 2026-05-28 |
| Bruce D. Steel | 男 | Chief Executive Officer and Director | 59 | 425.52万美元 | 490.81 | 2026-05-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason A. Keyes | 男 | Chief Financial Officer | 55 | 未披露 | 未持股 | 2026-05-28 |
| Stephen Connelly | 男 | Chief Scientific Officer and President | 45 | 270.18万美元 | 154.26 | 2026-05-28 |
| Christine Zedelmayer | 女 | Chief Operating Officer | 56 | 210.21万美元 | 65.22 | 2026-05-28 |
| Bruce D. Steel | 男 | Chief Executive Officer and Director | 59 | 425.52万美元 | 490.81 | 2026-05-28 |
董事简历
中英对照 | 中文 | 英文- Barbara Troupin
-
Barbara Troupin，从2006年到2014年，在VIVUS，Inc.担任医疗事务和临床开发方面的多个高级管理职务。在这些角色中，Troupin博士是Qsymia 3期项目的首席临床医生，是Qsymia新药申请所有医学审查的主要贡献者，并且是成功的Qsymia FDA咨询委员会会议的主要医学陈述人。在此之前，Troupin博士曾在Profil Institute for Clinical Research和Radiant Research担任医疗总监职务，这两家机构都是合同研究组织。Troupin博士获得了宾夕法尼亚大学医学院的医学博士学位和沃顿商学院的工商管理硕士学位。
Barbara Troupin has served as a member of Equillium, Inc.'s Board since February 2022. Dr. Troupin has worked as a fractional Chief Medical Officer for Laguna Biotherapeutics Inc. since May 2023, and previously as a strategic advisor and advisory board member for Atacana, Inc. from January 2024 until December 2025, a strategic advisor for Terns Pharmaceuticals, Inc. from October 2024 until March 2025, and as a senior clinical advisor and advisory board member for Ilant Health, Inc. from May 2023 until December 2024. She also has been a member of the board of directors at ProSciento, a private equity backed privately held clinical research organization, since January 2025. Dr. Troupin was the Senior Vice President, Medical Affairs at MyoKardia, Inc., a publicly held biopharmaceutical company, from April 2020 until March 2021, where she was responsible for launch preparation in the United States and European Union through the time of MyoKardia's acquisition by and integration into Bristol Myers Squibb. Prior to joining MyoKardia, Dr. Troupin was the Chief Medical Officer of ERX Pharmaceuticals, a privately held pharmaceutical company, from December 2018 until December 2019. Prior to that, Dr. Troupin held positions with Aquinox Pharmaceuticals, Inc., a publicly held pharmaceutical company, as the Chief Medical Officer, Vice President of Clinical Development and Regulatory Affairs between March 2017 and July 2018, and Chief Medical Officer, Vice President of Clinical Development between October 2016 and March 2017. Dr. Troupin received her Doctorate in Medicine from the University of Pennsylvania School of Medicine where she also completed her M.B.A. from the Wharton School of Business, with an emphasis in health care management. She holds a B.A. in Biochemistry and Cell Biology from the University of California San Diego. - Barbara Troupin，从2006年到2014年，在VIVUS，Inc.担任医疗事务和临床开发方面的多个高级管理职务。在这些角色中，Troupin博士是Qsymia 3期项目的首席临床医生，是Qsymia新药申请所有医学审查的主要贡献者，并且是成功的Qsymia FDA咨询委员会会议的主要医学陈述人。在此之前，Troupin博士曾在Profil Institute for Clinical Research和Radiant Research担任医疗总监职务，这两家机构都是合同研究组织。Troupin博士获得了宾夕法尼亚大学医学院的医学博士学位和沃顿商学院的工商管理硕士学位。
- Barbara Troupin has served as a member of Equillium, Inc.'s Board since February 2022. Dr. Troupin has worked as a fractional Chief Medical Officer for Laguna Biotherapeutics Inc. since May 2023, and previously as a strategic advisor and advisory board member for Atacana, Inc. from January 2024 until December 2025, a strategic advisor for Terns Pharmaceuticals, Inc. from October 2024 until March 2025, and as a senior clinical advisor and advisory board member for Ilant Health, Inc. from May 2023 until December 2024. She also has been a member of the board of directors at ProSciento, a private equity backed privately held clinical research organization, since January 2025. Dr. Troupin was the Senior Vice President, Medical Affairs at MyoKardia, Inc., a publicly held biopharmaceutical company, from April 2020 until March 2021, where she was responsible for launch preparation in the United States and European Union through the time of MyoKardia's acquisition by and integration into Bristol Myers Squibb. Prior to joining MyoKardia, Dr. Troupin was the Chief Medical Officer of ERX Pharmaceuticals, a privately held pharmaceutical company, from December 2018 until December 2019. Prior to that, Dr. Troupin held positions with Aquinox Pharmaceuticals, Inc., a publicly held pharmaceutical company, as the Chief Medical Officer, Vice President of Clinical Development and Regulatory Affairs between March 2017 and July 2018, and Chief Medical Officer, Vice President of Clinical Development between October 2016 and March 2017. Dr. Troupin received her Doctorate in Medicine from the University of Pennsylvania School of Medicine where she also completed her M.B.A. from the Wharton School of Business, with an emphasis in health care management. She holds a B.A. in Biochemistry and Cell Biology from the University of California San Diego.
- Charles McDermott
-
Charles McDermott自2018年9月起担任董事会成员。McDermott先生自2019年3月起担任Primmune Therapeutics，Inc.（一家私人持有的生物技术公司）的董事长，总裁兼首席执行官。McDermott先生于2017年9月至2018年5月担任Impact Biomedicines，Inc.（一家私人持有的生物技术公司）的总裁兼首席商务官。在此之前，麦克德莫特先生于2015年6月至2017年8月担任上市生物制药公司Kala制药有限公司的总裁兼首席商务官。此前，他曾于2014年10月至2015年6月担任Kala的临时总裁兼首席商务官，并于2013年6月至2014年10月担任Kala业务发展执行Vice President。在加入Kala公司之前，McDermott先生曾于2005年4月至2013年5月在Allergan plc公司（一家上市的全球制药公司）担任业务发展、眼部护理和药物输送的董事和Vice President。加入Allergan之前，McDermott从2001年1月到2005年3月在Decode Genetics，Inc.（现为DGI Resolutions，Inc.，一家私营生物制药公司）担任多个业务开发职位。在Decode Genetics之前，McDermott先生是Agouron Pharmaceuticals，Inc.血管生成药理学小组的研究科学家。McDermott先生目前担任欧米茄基金（Omega Funds）的顾问，这是一家创建和投资生命科学公司的投资公司。McDermott先生拥有圣地亚哥大学（University of San Diego）的工商管理硕士学位，加州大学圣巴巴拉分校（University of California at Santa Barbara）的分子，细胞和发育生物学硕士学位，California University of Santa Cruz生物化学和分子生物学学士学位以及University of California San Diego Extension临床试验设计和管理证书。
Charles McDermott has served as a member of Equillium, Inc.'s Board since September 2018. Mr. McDermott has served on the board of directors and as President and Chief Executive Officer of Primmune Therapeutics, Inc., a privately held biotechnology company, since March 2019. Mr. McDermott has served as a Managing Member of McDermott Consulting, LLC since September 2018. From September 2017 to May 2018, Mr. McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately held biotechnology company. Prior to that, Mr. McDermott served as President and Chief Business Officer of Kala Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from June 2015 to August 2017. Mr. McDermott currently serves as chairman of the board of directors of Anavo Therapeutics GmbH, a privately held biotechnology company. Mr. McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension. - Charles McDermott自2018年9月起担任董事会成员。McDermott先生自2019年3月起担任Primmune Therapeutics，Inc.（一家私人持有的生物技术公司）的董事长，总裁兼首席执行官。McDermott先生于2017年9月至2018年5月担任Impact Biomedicines，Inc.（一家私人持有的生物技术公司）的总裁兼首席商务官。在此之前，麦克德莫特先生于2015年6月至2017年8月担任上市生物制药公司Kala制药有限公司的总裁兼首席商务官。此前，他曾于2014年10月至2015年6月担任Kala的临时总裁兼首席商务官，并于2013年6月至2014年10月担任Kala业务发展执行Vice President。在加入Kala公司之前，McDermott先生曾于2005年4月至2013年5月在Allergan plc公司（一家上市的全球制药公司）担任业务发展、眼部护理和药物输送的董事和Vice President。加入Allergan之前，McDermott从2001年1月到2005年3月在Decode Genetics，Inc.（现为DGI Resolutions，Inc.，一家私营生物制药公司）担任多个业务开发职位。在Decode Genetics之前，McDermott先生是Agouron Pharmaceuticals，Inc.血管生成药理学小组的研究科学家。McDermott先生目前担任欧米茄基金（Omega Funds）的顾问，这是一家创建和投资生命科学公司的投资公司。McDermott先生拥有圣地亚哥大学（University of San Diego）的工商管理硕士学位，加州大学圣巴巴拉分校（University of California at Santa Barbara）的分子，细胞和发育生物学硕士学位，California University of Santa Cruz生物化学和分子生物学学士学位以及University of California San Diego Extension临床试验设计和管理证书。
- Charles McDermott has served as a member of Equillium, Inc.'s Board since September 2018. Mr. McDermott has served on the board of directors and as President and Chief Executive Officer of Primmune Therapeutics, Inc., a privately held biotechnology company, since March 2019. Mr. McDermott has served as a Managing Member of McDermott Consulting, LLC since September 2018. From September 2017 to May 2018, Mr. McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately held biotechnology company. Prior to that, Mr. McDermott served as President and Chief Business Officer of Kala Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from June 2015 to August 2017. Mr. McDermott currently serves as chairman of the board of directors of Anavo Therapeutics GmbH, a privately held biotechnology company. Mr. McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension.
- Daniel M. Bradbury
-
Daniel M. Bradbury，自2020年1月起担任董事会执行主席，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任首席执行官。Bradbury先生是Equillium的联合创始人，并于2017年3月至2018年6月担任总裁。他是BioBrit， LLC（生命科学咨询和投资公司）的创始人和管理成员（2012年9月以来）。2007年3月至2012年8月Amylin被百时美施贵宝公司（Bristol-Myers Squibb company）收购，他担任Amylin Pharmaceuticals， Inc.（一家上市的生物制药公司）的总裁、首席执行官和董事。Bradbury先生自2019年7月起担任Castle Biosciences， Inc 。的董事会成员，他还担任薪酬委员会成员和董事会主席。他自2019年1月起担任Biocon Biologics Ltd.的董事会成员，并担任审计委员会成员。他自2024年3月起担任Vivani Medical， Inc.的董事会成员，在那里他还担任审计委员会成员。此外，他还担任许多私人公司的董事会成员。他曾担任Intercept Pharmaceuticals， Inc.（一家上市的生物技术公司）的董事会成员（从2016年到2023年）；Biocon Ltd.，一家上市的生物制药公司，从2013年到2022年；concept Therapeutics Incorporated，一家上市的生物技术公司，从2012年到2019年；Geron Corporation，一家上市的生物技术公司，从2012年到2019年；Illumina, Inc.（一家上市的生物技术公司），从2004年到2017年；Panacea Acquisition Corporation（一家上市的特殊目的收购公司），从2020年到2021年。他持有Nottingham大学的药学学士学位，以及Harrow and Ealing Colleges of Higher Education的管理学文凭。
Daniel M. Bradbury has served as the Chairman of the Board since September 2025 and has been a member of Equillium, Inc.'s Board since March 2017. He served as Equillium, Inc.'s Executive Chairman of the Board from January 2020 to September 2025. He served as Equillium, Inc.'s Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co founder of Equillium and served as Equillium, Inc.'s President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC ("BioBrit"), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol Myers Squibb Company in August 2012. Mr. Bradbury has served on the board of directors of Castle Biosciences, Inc since July 2019, where he also serves on the compensation committee and as chairman of the board. He has served on the board of directors of Biocon Biologics Ltd. since January 2019, where he also serves on the audit committee. He has served on the board of directors of Vivani Medical, Inc. since March 2024, where he also serves on the audit committee.Additionally, Mr. Bradbury serves on the boards of many private companies. Mr. Bradbury previously served on the boards of directors of Intercept Pharmaceuticals, Inc., a publicly held biotechnology company, from 2016 to 2023; Biocon Ltd., a publicly held biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics Incorporated, a publicly held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly held biotechnology company, from 2004 to 2017; and Panacea Acquisition Corporation, a publicly held special purpose acquisition company, from 2020 to 2021. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom. - Daniel M. Bradbury，自2020年1月起担任董事会执行主席，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任首席执行官。Bradbury先生是Equillium的联合创始人，并于2017年3月至2018年6月担任总裁。他是BioBrit， LLC（生命科学咨询和投资公司）的创始人和管理成员（2012年9月以来）。2007年3月至2012年8月Amylin被百时美施贵宝公司（Bristol-Myers Squibb company）收购，他担任Amylin Pharmaceuticals， Inc.（一家上市的生物制药公司）的总裁、首席执行官和董事。Bradbury先生自2019年7月起担任Castle Biosciences， Inc 。的董事会成员，他还担任薪酬委员会成员和董事会主席。他自2019年1月起担任Biocon Biologics Ltd.的董事会成员，并担任审计委员会成员。他自2024年3月起担任Vivani Medical， Inc.的董事会成员，在那里他还担任审计委员会成员。此外，他还担任许多私人公司的董事会成员。他曾担任Intercept Pharmaceuticals， Inc.（一家上市的生物技术公司）的董事会成员（从2016年到2023年）；Biocon Ltd.，一家上市的生物制药公司，从2013年到2022年；concept Therapeutics Incorporated，一家上市的生物技术公司，从2012年到2019年；Geron Corporation，一家上市的生物技术公司，从2012年到2019年；Illumina, Inc.（一家上市的生物技术公司），从2004年到2017年；Panacea Acquisition Corporation（一家上市的特殊目的收购公司），从2020年到2021年。他持有Nottingham大学的药学学士学位，以及Harrow and Ealing Colleges of Higher Education的管理学文凭。
- Daniel M. Bradbury has served as the Chairman of the Board since September 2025 and has been a member of Equillium, Inc.'s Board since March 2017. He served as Equillium, Inc.'s Executive Chairman of the Board from January 2020 to September 2025. He served as Equillium, Inc.'s Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co founder of Equillium and served as Equillium, Inc.'s President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC ("BioBrit"), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol Myers Squibb Company in August 2012. Mr. Bradbury has served on the board of directors of Castle Biosciences, Inc since July 2019, where he also serves on the compensation committee and as chairman of the board. He has served on the board of directors of Biocon Biologics Ltd. since January 2019, where he also serves on the audit committee. He has served on the board of directors of Vivani Medical, Inc. since March 2024, where he also serves on the audit committee.Additionally, Mr. Bradbury serves on the boards of many private companies. Mr. Bradbury previously served on the boards of directors of Intercept Pharmaceuticals, Inc., a publicly held biotechnology company, from 2016 to 2023; Biocon Ltd., a publicly held biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics Incorporated, a publicly held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly held biotechnology company, from 2004 to 2017; and Panacea Acquisition Corporation, a publicly held special purpose acquisition company, from 2020 to 2021. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom.
- Mark Pruzanski
-
Mark Pruzanski，医学博士，是Intercept Pharmaceuticals, Inc.的联合成立者，自2002年公司成立以来担任Intercept Pharmaceuticals, Inc.的首席执行官和总裁，以及公司董事。他有着超过15年的生命科学公司管理、风险资本和战略咨询方面的经验。Pruzanski博士早前曾是Apple Tree Partners（他于1999年联合成立的早期阶段生命科学风险资本企业）的风险投资合伙人。在那之前，他曾是Oak Investment Partners的常驻企业家。Pruzanski博士获得了安大略McMaster University的医学博士学位， 意大利博洛尼亚和华盛顿特区the Johns Hopkins University School of Advanced International Studies的国际事务硕士学位，魁北克蒙特利尔McGill University的学士学位。他目前担任 Emerging Company Section of the Biotechnology Industry Association BIO 和 the Foundation for the Defense of Democracies（华盛顿特区的一个智库）的董事。Pruzanski博士是大量科学出版物的合著人，以及关于候选人和科学发现的几项专利的发明人。
Mark Pruzanski has served as a member of Equillium, Inc.'s Board since September 2018. Dr. Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences sector. He has served as the Chief Executive Officer Alentis Therapeutics AG since October 2025 and a member of its board of directors since December 2025. Previously, he served as Chief Executive Officer of Versanis Bio, a clinical stage biotechnology company, from April 2022 to September 2023, where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company's acquisition in 2023 by Eli Lilly and Company, and as a member of the board from September 2021 to August 2023. Dr. Pruzanski was also a co founder and member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly held biopharmaceutical company where he served as President and Chief Executive Officer from September 2002 until January 2021. Prior to co founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm that he co founded, and an entrepreneur in residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co author of a number of scientific publications and is named as an inventor on several patents. Additionally, Dr. Pruzanski currently serves on the boards of multiple private companies, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), a biotechnology focused trade association, and the Foundation for Defense of Democracies, a non profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor's degree from McGill University in Montreal, Canada. - Mark Pruzanski，医学博士，是Intercept Pharmaceuticals, Inc.的联合成立者，自2002年公司成立以来担任Intercept Pharmaceuticals, Inc.的首席执行官和总裁，以及公司董事。他有着超过15年的生命科学公司管理、风险资本和战略咨询方面的经验。Pruzanski博士早前曾是Apple Tree Partners（他于1999年联合成立的早期阶段生命科学风险资本企业）的风险投资合伙人。在那之前，他曾是Oak Investment Partners的常驻企业家。Pruzanski博士获得了安大略McMaster University的医学博士学位， 意大利博洛尼亚和华盛顿特区the Johns Hopkins University School of Advanced International Studies的国际事务硕士学位，魁北克蒙特利尔McGill University的学士学位。他目前担任 Emerging Company Section of the Biotechnology Industry Association BIO 和 the Foundation for the Defense of Democracies（华盛顿特区的一个智库）的董事。Pruzanski博士是大量科学出版物的合著人，以及关于候选人和科学发现的几项专利的发明人。
- Mark Pruzanski has served as a member of Equillium, Inc.'s Board since September 2018. Dr. Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences sector. He has served as the Chief Executive Officer Alentis Therapeutics AG since October 2025 and a member of its board of directors since December 2025. Previously, he served as Chief Executive Officer of Versanis Bio, a clinical stage biotechnology company, from April 2022 to September 2023, where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company's acquisition in 2023 by Eli Lilly and Company, and as a member of the board from September 2021 to August 2023. Dr. Pruzanski was also a co founder and member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly held biopharmaceutical company where he served as President and Chief Executive Officer from September 2002 until January 2021. Prior to co founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm that he co founded, and an entrepreneur in residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co author of a number of scientific publications and is named as an inventor on several patents. Additionally, Dr. Pruzanski currently serves on the boards of multiple private companies, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), a biotechnology focused trade association, and the Foundation for Defense of Democracies, a non profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor's degree from McGill University in Montreal, Canada.
- Martha J. Demski
-
自2005年以来Martha J. Demski一直担任Equillium, Inc.的董事之一。自2011年8月以来她曾担任 Ajinimoto Althea, Inc. formerly Althea Technologies, Inc（全面集成的开发和生产组织）的高级副总裁兼首席财务官。从2008年7月到2010年12月她担任idney Kimmel Cancer Center （SKCC）（一个从事生物医学研究在2009年自愿申请破产非盈利的公司）的临时首席运营官和首席财务官。2006年4月至2008年5月担任U.S. Trust的高级副总裁。从2005年到2008年7月就职于Trustees at SKCC董事，审计委员会主席以及管理和提名委员会主席。从1988年12月到2004年6月担任Vical Incorporated（一家生物制药公司）副总裁、首席财务官、财务主管兼总监。她也担任Adamas Pharmaceuticals, Inc董事和审计委员会主席。她在密歇根州立大学获得了文学学士学位和芝加哥大学布斯商学院工商管理硕士学位。
Martha J. Demski,has served as a director since August 2023. Ms. Demski has extensive strategic, operational, biotech, and financial leadership experience. She has significant public company board experience, having served in various roles including Chair of the Board, Lead Independent Director, Audit Committee Chair, and Compensation Committee Member. She has served on the boards of Chimerix, Inc., Equillium, Inc., Adamas Pharmaceuticals, Inc., and ADMA Biologics, Inc. Ms. Demski also has extensive executive leadership experience, including serving as Chief Financial Officer and Chief Operating Officer at multiple companies. In addition, she spent 13 years with Bank of America, where she was an early leader in banking services for biotech companies in the San Diego region beginning in 1978. She has also served as a board member and advisor to various private companies and philanthropic organizations. Ms. Demski holds a B.A. from Michigan State University and an M.B.A. from the University of Chicago Booth School of Business, with concentrations in finance and accounting. In 2017, she received the Director of the Year in Corporate Governance award from the Corporate Directors Forum. - 自2005年以来Martha J. Demski一直担任Equillium, Inc.的董事之一。自2011年8月以来她曾担任 Ajinimoto Althea, Inc. formerly Althea Technologies, Inc（全面集成的开发和生产组织）的高级副总裁兼首席财务官。从2008年7月到2010年12月她担任idney Kimmel Cancer Center （SKCC）（一个从事生物医学研究在2009年自愿申请破产非盈利的公司）的临时首席运营官和首席财务官。2006年4月至2008年5月担任U.S. Trust的高级副总裁。从2005年到2008年7月就职于Trustees at SKCC董事，审计委员会主席以及管理和提名委员会主席。从1988年12月到2004年6月担任Vical Incorporated（一家生物制药公司）副总裁、首席财务官、财务主管兼总监。她也担任Adamas Pharmaceuticals, Inc董事和审计委员会主席。她在密歇根州立大学获得了文学学士学位和芝加哥大学布斯商学院工商管理硕士学位。
- Martha J. Demski,has served as a director since August 2023. Ms. Demski has extensive strategic, operational, biotech, and financial leadership experience. She has significant public company board experience, having served in various roles including Chair of the Board, Lead Independent Director, Audit Committee Chair, and Compensation Committee Member. She has served on the boards of Chimerix, Inc., Equillium, Inc., Adamas Pharmaceuticals, Inc., and ADMA Biologics, Inc. Ms. Demski also has extensive executive leadership experience, including serving as Chief Financial Officer and Chief Operating Officer at multiple companies. In addition, she spent 13 years with Bank of America, where she was an early leader in banking services for biotech companies in the San Diego region beginning in 1978. She has also served as a board member and advisor to various private companies and philanthropic organizations. Ms. Demski holds a B.A. from Michigan State University and an M.B.A. from the University of Chicago Booth School of Business, with concentrations in finance and accounting. In 2017, she received the Director of the Year in Corporate Governance award from the Corporate Directors Forum.
- Bruce D. Steel
-
BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
Bruce D. Steel has served as Equillium, Inc.'s Chief Executive Officer since January 2020 and as a member of Equillium, Inc.'s board of directors since March 2017. He served as Equillium, Inc.'s President and Chief Executive Officer from December 2019 through September 2025. He served as Equillium, Inc.'s President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately held pharmaceutical company. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst. - BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
- Bruce D. Steel has served as Equillium, Inc.'s Chief Executive Officer since January 2020 and as a member of Equillium, Inc.'s board of directors since March 2017. He served as Equillium, Inc.'s President and Chief Executive Officer from December 2019 through September 2025. He served as Equillium, Inc.'s President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately held pharmaceutical company. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.
高管简历
中英对照 | 中文 | 英文- Jason A. Keyes
JasonA.Keyes自2020年2月起担任董事会成员。凯斯先生曾担任Equillium，Inc.的首席财务官。纳斯达克股票代码:EQ自2018年3月以来。在加入Equillium之前，他于2016年6月至2018年2月担任OrexigenTherapeutics，Inc.执行Vice President兼首席财务官，在为产品组合的全球商业化制定业务和财务战略方面发挥了关键作用。在担任首席财务官之前，凯斯先生于2015年2月至2016年6月担任Orexigen财务Vice President。在此之前，2007年8月至2013年1月，凯斯先生在AmylinPharmaceuticals，Inc.公司（一家上市生物制药公司）担任越来越重要的职务。在其职业生涯早期，凯斯先生曾在Amgen，Inc.（一家上市生物制药公司）和Baxter梦百合Corporation（一家上市梦百合公司）担任财务和公司战略领导职务。在他的职业生涯中，Keyes先生一直负责领导整个生物技术价值链的财务规划，管理投资者关系，筹集资金并推动业务发展。
Jason A. Keyes,has served as Chief Financial Officer since March 2018 and also has served as a director of Australian subsidiary since January 2019. Mr. Keyes currently serves on the board of directors and as the chair of the audit committee of Actuate Therapeutics, Inc., a publicly-held biopharmaceutical company. Mr. Keyes formerly served on the board of directors, including as chair of the audit committee, of Sesen Bio, Inc., a publicly-held biopharmaceutical company, from 2020 to 2023. From January 2013 to February 2018, Mr. Keyes held positions of increasing responsibility at Orexigen Therapeutics, Inc., a publicly-held pharmaceutical company which filed a voluntary petition for Chapter 11 bankruptcy in March 2018, most recently as Executive Vice President and Chief Financial Officer. Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013, most recently as Senior Director of Finance. Earlier in his career, Mr. Keyes held positions of increasing responsibility in finance and corporate strategy at Amgen, Inc., a publicly-held biopharmaceutical company, and at Baxter Healthcare Corporation, a publicly-held healthcare company. Mr. Keyes received his B.S. and M.S. degrees in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Mr. Keyes has tendered his resignation from all positions with Equillium, Inc. and Equillium, Inc. subsidiaries, effective as of April 25, 2025, to pursue other interests.- JasonA.Keyes自2020年2月起担任董事会成员。凯斯先生曾担任Equillium，Inc.的首席财务官。纳斯达克股票代码:EQ自2018年3月以来。在加入Equillium之前，他于2016年6月至2018年2月担任OrexigenTherapeutics，Inc.执行Vice President兼首席财务官，在为产品组合的全球商业化制定业务和财务战略方面发挥了关键作用。在担任首席财务官之前，凯斯先生于2015年2月至2016年6月担任Orexigen财务Vice President。在此之前，2007年8月至2013年1月，凯斯先生在AmylinPharmaceuticals，Inc.公司（一家上市生物制药公司）担任越来越重要的职务。在其职业生涯早期，凯斯先生曾在Amgen，Inc.（一家上市生物制药公司）和Baxter梦百合Corporation（一家上市梦百合公司）担任财务和公司战略领导职务。在他的职业生涯中，Keyes先生一直负责领导整个生物技术价值链的财务规划，管理投资者关系，筹集资金并推动业务发展。
- Jason A. Keyes,has served as Chief Financial Officer since March 2018 and also has served as a director of Australian subsidiary since January 2019. Mr. Keyes currently serves on the board of directors and as the chair of the audit committee of Actuate Therapeutics, Inc., a publicly-held biopharmaceutical company. Mr. Keyes formerly served on the board of directors, including as chair of the audit committee, of Sesen Bio, Inc., a publicly-held biopharmaceutical company, from 2020 to 2023. From January 2013 to February 2018, Mr. Keyes held positions of increasing responsibility at Orexigen Therapeutics, Inc., a publicly-held pharmaceutical company which filed a voluntary petition for Chapter 11 bankruptcy in March 2018, most recently as Executive Vice President and Chief Financial Officer. Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013, most recently as Senior Director of Finance. Earlier in his career, Mr. Keyes held positions of increasing responsibility in finance and corporate strategy at Amgen, Inc., a publicly-held biopharmaceutical company, and at Baxter Healthcare Corporation, a publicly-held healthcare company. Mr. Keyes received his B.S. and M.S. degrees in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Mr. Keyes has tendered his resignation from all positions with Equillium, Inc. and Equillium, Inc. subsidiaries, effective as of April 25, 2025, to pursue other interests.
- Stephen Connelly
Stephen Connelly，自2018年1月起担任首席科学官，2017年3月至2025年9月担任董事会成员。2025年9月30日，董事会任命康奈利博士为公司总裁。Connelly博士是Equillium的联合创始人，并于2017年3月至2018年1月期间担任顾问。2016年3月至2017年3月，康奈利博士在BioMed Realty，LP旗下投资公司BioMed Ventures担任负责人。2014年3月至2016年3月，Connelly博士在上市生物技术公司aTyr制药，Inc.担任业务发展和治疗联盟总监。Connelly博士在开展新颖创新研究方面拥有丰富的经验，发表了30多篇原创科学论文和专利。Connelly博士在英国埃克塞特大学获得药物化学学士学位和生物化学博士学位，并在加州大学圣地亚哥分校Rady学院获得工商管理硕士学位。
Stephen Connelly,has served as Chief Scientific Officer since January 2018 and as a member of Board from March 2017 to September 2025. On September 30, 2025, the Board appointed Dr. Connelly as the Company's President. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, from March 2016 until March 2017. From March 2014 to March 2016, Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.- Stephen Connelly，自2018年1月起担任首席科学官，2017年3月至2025年9月担任董事会成员。2025年9月30日，董事会任命康奈利博士为公司总裁。Connelly博士是Equillium的联合创始人，并于2017年3月至2018年1月期间担任顾问。2016年3月至2017年3月，康奈利博士在BioMed Realty，LP旗下投资公司BioMed Ventures担任负责人。2014年3月至2016年3月，Connelly博士在上市生物技术公司aTyr制药，Inc.担任业务发展和治疗联盟总监。Connelly博士在开展新颖创新研究方面拥有丰富的经验，发表了30多篇原创科学论文和专利。Connelly博士在英国埃克塞特大学获得药物化学学士学位和生物化学博士学位，并在加州大学圣地亚哥分校Rady学院获得工商管理硕士学位。
- Stephen Connelly,has served as Chief Scientific Officer since January 2018 and as a member of Board from March 2017 to September 2025. On September 30, 2025, the Board appointed Dr. Connelly as the Company's President. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, from March 2016 until March 2017. From March 2014 to March 2016, Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.
- Christine Zedelmayer
Christine Zedelmayer，自2020年1月起担任首席运营官。Zedelmayer女士于2018年2月至2019年12月担任运营副总裁。Zedelmayer女士目前担任拉斯维加斯内华达大学经济发展办公室的战略顾问。Zedelmayer女士在2012年至2018年期间拥有并曾担任Centerra Consulting，LLC的首席顾问，该公司是一家专注于生命科学的项目管理和投资者关系咨询公司，在那里她领导了客户的战略业务发展项目，并担任多家医疗器械公司的投资者关系主管。在加入Centerra之前，从2003年到2012年，Zedelmayer女士曾在一家上市生物制药公司Amylin Pharmaceuticals, Inc.担任过多种职务，包括Alliance Management高级总监，在那里她领导了与礼来的全球合作，并担任投资者关系执行董事。在其职业生涯的早期，Zedelmayer女士曾在上市生物制药公司安进公司、上市制药公司Ligand制药公司以及礼来公司的诊断子公司Hybritech担任工程和项目管理方面的职责越来越重的职位。Zedelmayer女士在圣地亚哥州立大学获得电气工程学士学位，并在加州路德大学获得金融硕士学位。
Christine Zedelmayer,has served as Chief Operating Officer since January 2020. Ms. Zedelmayer served as Vice President of Operations from February 2018 through December 2019. Ms. Zedelmayer currently serves as a strategic advisor to the Office of Economic Development at the University of Nevada, Las Vegas. Ms. Zedelmayer owns and was previously principal consultant at Centerra Consulting, LLC, a project management and investor relations consulting firm focused on life sciences, from 2012 to 2018, where she led strategic business development projects for clients and served as head of investor relations for a variety of medical device companies. Prior to Centerra, from 2003 to 2012, Ms. Zedelmayer held a variety of roles at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, including Senior Director of Alliance Management, where she led the global collaboration with Eli Lilly and as Executive Director of Investor Relations. Earlier in her career, Ms. Zedelmayer held positions of increasing responsibility in engineering and program management at Amgen, Inc., a publicly held biopharmaceutical company, Ligand Pharmaceuticals, a publicly-held pharmaceutical company and at Hybritech, a diagnostics subsidiary of Eli Lilly & Company. Ms. Zedelmayer received her B.S. in Electrical Engineering from San Diego State University and an M.B.A. with Finance emphasis from California Lutheran University.- Christine Zedelmayer，自2020年1月起担任首席运营官。Zedelmayer女士于2018年2月至2019年12月担任运营副总裁。Zedelmayer女士目前担任拉斯维加斯内华达大学经济发展办公室的战略顾问。Zedelmayer女士在2012年至2018年期间拥有并曾担任Centerra Consulting，LLC的首席顾问，该公司是一家专注于生命科学的项目管理和投资者关系咨询公司，在那里她领导了客户的战略业务发展项目，并担任多家医疗器械公司的投资者关系主管。在加入Centerra之前，从2003年到2012年，Zedelmayer女士曾在一家上市生物制药公司Amylin Pharmaceuticals, Inc.担任过多种职务，包括Alliance Management高级总监，在那里她领导了与礼来的全球合作，并担任投资者关系执行董事。在其职业生涯的早期，Zedelmayer女士曾在上市生物制药公司安进公司、上市制药公司Ligand制药公司以及礼来公司的诊断子公司Hybritech担任工程和项目管理方面的职责越来越重的职位。Zedelmayer女士在圣地亚哥州立大学获得电气工程学士学位，并在加州路德大学获得金融硕士学位。
- Christine Zedelmayer,has served as Chief Operating Officer since January 2020. Ms. Zedelmayer served as Vice President of Operations from February 2018 through December 2019. Ms. Zedelmayer currently serves as a strategic advisor to the Office of Economic Development at the University of Nevada, Las Vegas. Ms. Zedelmayer owns and was previously principal consultant at Centerra Consulting, LLC, a project management and investor relations consulting firm focused on life sciences, from 2012 to 2018, where she led strategic business development projects for clients and served as head of investor relations for a variety of medical device companies. Prior to Centerra, from 2003 to 2012, Ms. Zedelmayer held a variety of roles at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, including Senior Director of Alliance Management, where she led the global collaboration with Eli Lilly and as Executive Director of Investor Relations. Earlier in her career, Ms. Zedelmayer held positions of increasing responsibility in engineering and program management at Amgen, Inc., a publicly held biopharmaceutical company, Ligand Pharmaceuticals, a publicly-held pharmaceutical company and at Hybritech, a diagnostics subsidiary of Eli Lilly & Company. Ms. Zedelmayer received her B.S. in Electrical Engineering from San Diego State University and an M.B.A. with Finance emphasis from California Lutheran University.
- Bruce D. Steel
BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
Bruce D. Steel has served as Equillium, Inc.'s Chief Executive Officer since January 2020 and as a member of Equillium, Inc.'s board of directors since March 2017. He served as Equillium, Inc.'s President and Chief Executive Officer from December 2019 through September 2025. He served as Equillium, Inc.'s President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately held pharmaceutical company. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.- BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
- Bruce D. Steel has served as Equillium, Inc.'s Chief Executive Officer since January 2020 and as a member of Equillium, Inc.'s board of directors since March 2017. He served as Equillium, Inc.'s President and Chief Executive Officer from December 2019 through September 2025. He served as Equillium, Inc.'s President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately held pharmaceutical company. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.